J. Ubbink
MedDRAVedolizumabInfliximabEtanerceptDiscontinuationAdverse drug reactionPopulationFamily medicineClinical trialMedicine
1Publications
0Citations
Publications 1
Newest
Background: Chronic fatigue is a well-known symptom in patients with rheumatic diseases and other immune-mediated inflammatory diseases (IMIDs). Therefore, fatigue as an adverse drug reaction (ADR) to biologics may remain unrecognised or may erroneously be attributed to the disease. Objectives: To assess patient-reported fatigue attributed to biologics for IMIDs and investigate predisposing factors of patient-reported fatigue. Methods: The Dutch Biologic Monitor is a multicenter patient-reported...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.